President Donald Trump announced on Wednesday his intention to nominate Dr. Heidi Overton to serve as the next commissioner of the Food and Drug Administration. In a post shared via Truth Social, the president described Overton as a rockstar within his administration who has worked closely with figures like Secretary Robert F. Kennedy Jr. and Dr. Oz to advance what he called the most transformative health agenda in history. The appointment aims to fill the void left by former director Dr. Marty Makary, who stepped down in May.

A physician with an advanced degree from Johns Hopkins University, Overton comes to the nomination after serving as chief policy officer at the America First Policy Institute, a think tank dedicated to promoting the president’s core priorities. Trump believes her leadership will ensure that America First policies are championed across the agency, specifically regarding food safety and drug standards. He highlighted her ability to solve difficult problems and noted her involvement in pushing for favored nation deals with pharmaceutical companies to reduce prescription costs for Americans.

However, the path to confirmation may be fraught with challenges despite a narrow Republican majority in the Senate. Some lawmakers have already voiced significant reservations about her suitability for the role. Senator Bill Cassidy of Louisiana, himself a physician, questioned whether Overton possesses the necessary managerial experience to lead such a massive organization during a period of low staff morale. More pointedly, Cassidy criticized her role in a recent executive order concerning vaccines, suggesting that her actions call into question her commitment to sound science and child health.

Beyond vaccine controversies, Overton is expected to bring a conservative ideological shift to the agency’s approach toward reproductive health and medication access. She has been vocal in her criticism of abortion pills and aligns herself with activists seeking stricter regulations on their distribution. As she prepares for her Senate hearings, critics and supporters alike will likely clash over whether her loyalty to political objectives outweighs the traditional nonpartisan scientific rigor required to head one of the world’s most influential regulatory bodies.